Denali Therapeutics (DNLI) Shares Outstanding (Weighted Average) (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Shares Outstanding (Weighted Average) data on file, last reported at $186.6 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $186.6 million, up 28.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $186.6 million (up 28.56% YoY), and the FY2025 annual result was $172.6 million, up 21.05% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $186.6 million in Q1 2026 per DNLI's latest filing, from $172.6 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $186.6 million in Q1 2026 and troughed at $122.7 million in Q1 2022.
• A 5-year average of $145.3 million and a median of $140.2 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Weighted Average) retreated 8.69% in 2025, then rose 28.56% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $125.5 million in 2022, then rose by 9.43% to $137.4 million in 2023, then rose by 3.83% to $142.6 million in 2024, then gained by 21.05% to $172.6 million in 2025, then climbed by 8.1% to $186.6 million in 2026.
• Business Quant data shows DNLI's Shares Outstanding (Weighted Average) at $186.6 million in Q1 2026, $172.6 million in Q4 2025, and $172.4 million in Q3 2025.